TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06233799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended-release naltrexone (XR-NTX)
Description: Once per three weeks injections of extended-release naltrexone
Study: NCT05010746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Innovalve TMVR system
Description: Innovalve TMVR system
Study: NCT06233799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended release bupropion (BUP-XL) tablets (BUP-XL)
Description: Daily oral extended release bupropion tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: iPLB
Description: Once per three weeks injections of placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oPLB
Description: Daily oral placebo tablets
Study: NCT06240013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foam Rolling
Description: Participants will take a long sitting position on a solid and flat surface, positioning their arms back and transferring their body weight to their palms. The foam roller to be applied to the dominant side will be placed under the hamstrings and slowly moved back and forth from the ischial tuberosity to the popliteal fossa, applying pressure for 2 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation Stretching
Description: A PNF stretching protocol will be implemented with each participant assuming a tall sitting position on a solid, flat surface with their knees extended as much as possible. At this moment, the participant will be asked to perform maximum isometric hamstring muscle contraction for 5 seconds, followed by 5 seconds of relaxation and 20 seconds of stretching.
Study: NCT06177392

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Secondary TAVI access
Description: The randomization will determine whether radial or femoral artery puncture will be employed as the secondary access in the TAVI procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Secondary TAVI access
Description: The randomization will determine whether radial or femoral artery puncture will be employed as the secondary access in the TAVI procedure.
Study: NCT05623696

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham or actual non-invasive (Magnetic) brain stimulation
Description: 5 Hz rTMS applied using an actual or sham coil over the left or right DLPFC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham or actual non-invasive (Magnetic) brain stimulation
Description: 5 Hz rTMS applied using an actual or sham coil over the left or right DLPFC

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham or actual non-invasive (Magnetic) brain stimulation
Description: 5 Hz rTMS applied using an actual or sham coil over the left or right DLPFC
Study: NCT06092567

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group A ( Oblique Incremental Placement Technique)
Description: In this interventional group, a Nanohybrid composite resin Nexcomp (Meta Biomed, Korea) was placed using an oblique incremental technique with increments not exceeding 2 mm in thickness.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group B (Bulk-fill Placement technique)
Description: In this group, a composite Beautifil-Bulk Restorative (SHOFU dental) was utilized for restorative purposes using a bulk-fill technique with a thickness of 4 mm
Study: NCT05624151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine +Bupivacaine
Description: infraorbital nerve block by dexmedetomidine plus bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate + Bupivacaine
Description: infraorbital nerve block by magnesium sulphate plus bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: infraorbital nerve block by bupivacaine only
Study: NCT05036980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans Sodium Crocetinate
Description: Single IV bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans Sodium Crocetinate
Description: Single IV bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans Sodium Crocetinate
Description: Single IV bolus
Study: NCT06149325

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repetitive somatosensory stimulation (RSS)
Description: Tactile stimuli on the index finger of the intact hand, for a duration of 45 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repetitive somatosensory stimulation (RSS)
Description: Tactile stimuli on the index finger of the intact hand, for a duration of 45 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Repetitive somatosensory stimulation (RSS)
Description: Tactile stimuli on the index finger of the intact hand, for a duration of 4 minutes spread over 45 minutes in 6 blocks of 40 seconds

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Repetitive somatosensory stimulation (RSS)
Description: Tactile stimuli on the index finger of the intact hand, for a duration of 4 minutes spread over 45 minutes in 6 blocks of 40 seconds
Study: NCT06578741

Intervention type: DEVICE
Group type: OTHER
Intervention: GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device)
Description: Treatment with the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) in patients with Pararenal Abdominal Aortic Aneurysms and Thoracoabdominal Aortic Aneurysms
Study: NCT06033599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MORE and MI and NRT
Description: Eight group Mindfulness Oriented Recovery Enhancement sessions and one motivational interviewing session and nicotine replacement therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MORE and No MI and NRT
Description: Eight group Mindfulness Oriented Recovery Enhancement sessions and nicotine replacement therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Support Group and MI and NRT
Description: Eight group support group sessions and one motivational interviewing session and nicotine replacement therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Support Group and No MI and NRT
Description: Eight group support group sessions and and nicotine replacement therapy.
Study: NCT05127980

Intervention type: OTHER
Intervention: Data collection: Participant characteristics (Illness course, complications of primary EBV infection and provided treatments)
Description: Data collection: Participant characteristics (Illness course, complications of primary EBV infection and provided treatments) during 12 months (baseline visit and follow-up visits at 3, 6 and 12 months).

Intervention type: OTHER
Intervention: Data collection: Participant characteristics (Illness course, complications of primary EBV infection and provided treatments)
Description: Data collection: Participant characteristics (Illness course, complications of primary EBV infection and provided treatments) during 12 months (baseline visit and follow-up visits at 3, 6 and 12 months).

Intervention type: OTHER
Intervention: Data collection: blood samples (analysed for EBV serology, auto-antibody-testing/biobanking, RNA expression analyses, procalcitonin)
Description: Data collection: blood samples (analysed for EBV serology, auto-antibody-testing/biobanking, RNA expression analyses, procalcitonin) during 12 months (baseline visit and follow-up visits at 3, 6 and 12 months).

Intervention type: OTHER
Intervention: Data collection: blood samples (analysed for EBV serology, auto-antibody-testing/biobanking, RNA expression analyses, procalcitonin)
Description: Data collection: blood samples (analysed for EBV serology, auto-antibody-testing/biobanking, RNA expression analyses, procalcitonin) during 12 months (baseline visit and follow-up visits at 3, 6 and 12 months).

Intervention type: OTHER
Intervention: Data collection: Patient reported outcome (Fatigue questionnaires)
Description: Data collection: Patient reported outcome (Fatigue questionnaires) at 6 and 12 months.

Intervention type: OTHER
Intervention: Data collection: Patient reported outcome (Fatigue questionnaires)
Description: Data collection: Patient reported outcome (Fatigue questionnaires) at 6 and 12 months.
Study: NCT05502783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostamatinib
Description: Participants will receive fostamatinib 100 mg BID for 4 weeks. On the 4-week evaluation, a) if cytopenia improves (hemoglobin =10 g/dL, platelets = 50 x 109/L), patients will continue the same dose for a total of 12 weeks, b) if refractory cytopenias persist (hemoglobin \< 10 g/dL, platelets \< 50 x 109/L), the dose will be increased to 150 mg BID. Subjects with persistent (=2 readings, 2 weeks apart) loss of hematologic response after week 5 can increase their dose to 150 mg BID until at end of the study on week 12.
Study: NCT06430476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMI
Description: A phone-based intervention containing exercises meant to reduce ruminative thoughts carried out on an experience sampling platform m-Path

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EMA
Description: A phone-based exercise containing relaxation videos carried out on an experience sampling platform m-Path
Study: NCT05157243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Two NTZ 300 mg extended release tablets administered orally with food twice daily for 5 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin Super-B Complex
Description: Vitamin Super B-Complex administered orally twice daily for 5 days to maintain the blind

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin Super-B Complex
Description: Vitamin Super B-Complex administered orally twice daily for 5 days to maintain the blind

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two matching placebo tablets administered orally with food twice daily for 5 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Local standard of care for COVID-19

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Local standard of care for COVID-19
Study: NCT05774197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for pain
Description: Patient participating in this study will have survey assessments at baseline, 4 weeks (end of 4-week intervention period), and 6 weeks (end of 2-week post intervention period) assessing patient reported concerns, quality of life outcomes and usability of STAMP+CBT app. During this time, Patient will receive algorithm-based advice in response to their daily pain and mood surveys. These patients will be introduced to the extensive multi-media library of educational content covering medication support (e.g. using short and long-acting opioids, managing side effects, opioid safety); pain psychology (e.g. pain perception, pain and the stress response); health behaviors and pain (e.g. sleep hygiene); and skills training (e.g. activity pacing/ relaxation recordings).
Study: NCT06723886

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental arm: Olive pomace oil
Description: Participants will consume during 8 weeks either the test oil (olive pomace oil) as the only dietary fat. They will consume 45 g/day of oil, using it in salads, fried foods, as spread on toasts, etc.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-oleic acid sunflower oil
Description: Participants will consume during 8 weeks either the test active comparator oil (high-oleic acid sunflower oil) as the only dietary fat. They will consume 45 g/day of oil, using it in salads, fried foods, as spread on toasts, etc.
Study: NCT06715852

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PHYSBI: a 12-week physical exercise program
Description: An individualized 12-week training program including 3 occasions/week of moderate-high intensity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified eHealth Lift: a digital, evidence based lifestyle-intervention for health promotion.
Description: Through questionnaires, the patients answers questions regarding lifestyle habits and the results are converted into a health profile. A care manager will together with the patient decide appropriate health promoting activities to engage in.
Study: NCT06728267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stabilization training
Description: Exercise training will be given for 6 weeks, 3 days a week, 2 sets of 10 repetitions for the first two weeks, 2 sets of 15 repetitions for the second two weeks, and 3 sets of 12 repetitions for the third two weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: Routine training sessions conducted by coaches specific to the sport of underwater rugby.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Routine training sessions conducted by coaches specific to the sport of underwater rugby.
Study: NCT05587348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Best Practice Advisory
Description: Provider will get Best Practice Advisory or Message from DCE in intervention practices

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Best Practice Advisory
Description: Provider will get Best Practice Advisory or Message from DCE in intervention practices

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support
Description: Patients referred to DSMES classes will be randomized to get a peer supporter

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Peer Support
Description: Patients referred to DSMES classes will be randomized to get a peer supporter
Study: NCT06379061

Intervention type: OTHER
Intervention: Adult and Pediatrics
Description: This is an observational study. This protocol is for blood draw enrollment. These samples will be collected and binned by their results from the MeMed BV assay. Samples collected will be used for an analytical comparison study under a future testing protocol. These samples will be used to establish the diagnostic performance of MeMed BV test on BEC Access Immunoassay Systems for differentiating bacterial from viral infection.
Study: NCT06223360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Benfotiamine
Description: 300mg benfotiamine capsules (BID, twice a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Benfotiamine
Description: 600mg benfotiamine capsules (BID, twice a day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules to mimic benfotiamine capsules (BID, twice a day)
Study: NCT04822779

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sonopuls 490u, Enraf-Nonius, Rotterdam, Kingdom of the Netherlands
Description: Ultrasound therapy will be applied in continuous output, 1 MHz frequency, the intensity of 1.5 W / cm2, and duration 10 min per treatment, on the front of the shoulder, on the surface of 2 ultrasound heads (10 cm2).~The position of the arm will be in adduction and internal rotation in RCT of the supraspinatus, adduction and external rotation of the arm in RCT of the subscapularis, and the position of the arm over the opposite shoulder in RCT of the infraspinatus.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Sham ultrasound therapy will be applied using a frequency of 0 Hz, intensity 0 W / cm2, 10 min per treatment.~The position of the arm will be in adduction and internal rotation in RCT of the supraspinatus, adduction and external rotation of the arm in RCT of the subscapularis, and the position of the arm over the opposite shoulder in RCT of the infraspinatus.
Study: NCT05420233

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRE
Description: Magnetic Resonance Enterography at year 1 (in some patients)
Study: NCT05183776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional administration device
Description: The novel fractional administration device enable the administration of the microspheres in fractions determined by the user. For this study, 5 fractions of 20% will be administered and validated using MRI.
Study: NCT06013553

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: It comprised of parameters such as early mobilization and ambulatory training, pulmonary physiotherapy, active and passive normal joint movement exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercises group
Description: Standard physiotherapy + bicycle ergometer: In addition to the standard therapy, a bicycle ergometer for 20 minutes 5 days a week will be given.~Patients will turn the pedals of the bicycle while sitting on the edge of the bed.~In this protocol, a portable bicycle with adjustable pedal system, which can be placed on the edge of the bed, will be used.~Ratings of perceived exertion (RPE) will be used to determine the intensity of aerobic activity. According to the RPE, 10-12 strength exercises will be given
Study: NCT05290753

Intervention type: DRUG
Group type: OTHER
Intervention: Prokinetic Motility Agents as primpiram and gastreg
Description: Prospective cohort study to evaluate the effect of pro kinetic use in emergency intestinal anastomosis
Study: NCT06395051

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Monoester
Description: Ketone monoester supplement (395 mg/kg body mass)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be taste-matched to the active supplement for bitterness using denatonium benzoate and volume-matched with water
Study: NCT06144021

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey postbiotics derived from kefir lactic acid bacteria
Description: Kefir (alcoholic fermented dairy product made by fermenting cow, goat, or sheep milk) whey derived from lactic acid bacteria postbiotics

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder
Description: A powder product including Flavor, Calcium carbonate, Lactose, Maltodextrin, Sugar, Carboxy methyl cellulose. This cannot be distinguished from the postbiotics by inspection.
Study: NCT05155215

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IM19 CAR-T cells
Description: IM19 CAR-T cells will be administered at dose level: 100×10\^6 CAR-T cells or 200×10\^6 CAR-T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m\^2 per day for 3 days (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 per day for 3 days (IV)
Study: NCT05332236

Intervention type: DIAGNOSTIC_TEST
Intervention: Parent-Adolescent Communication Scale (questionnaire)
Description: Observational psychometric validation study

Intervention type: DIAGNOSTIC_TEST
Intervention: Parent-Adolescent Communication Scale (questionnaire)
Description: Observational psychometric validation study

Intervention type: DIAGNOSTIC_TEST
Intervention: Parent-Adolescent Communication Scale (questionnaire)
Description: Observational psychometric validation study
Study: NCT05208047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGT9486 plus sunitinib
Description: Participants will receive both CGT9486 and sunitinib orally until study stopping rules are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGT9486 plus sunitinib
Description: Participants will receive both CGT9486 and sunitinib orally until study stopping rules are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGT9486
Description: Participants will receive CGT9486 until steady state then both CGT9486 and sunitinib orally until study stopping rules are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Participants will receive sunitinib until steady state then both sunitinib and CGT9486 orally until study stopping rules are met.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: Participants will receive sunitinib orally until study stopping rules are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Participants will receive a single-dose of midazolam on Day 1 and Day 16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGT9486 plus sunitinib
Description: Patients will receive CGT9486 orally starting on Day 2 and sunitinib starting on Day 16 until study stopping rules are met.
Study: NCT05305170

Intervention type: DIAGNOSTIC_TEST
Intervention: Levels of EETs, DHETs and HETEs
Description: The plasmatic concentration of EETs, DHETs, and HETEs.

Intervention type: DIAGNOSTIC_TEST
Intervention: Levels of EETs, DHETs and HETEs
Description: The plasmatic concentration of EETs, DHETs, and HETEs.
Study: NCT05944718

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor
Description: Continuous Glucose Monitoring (CGM) is a technology used to measure glucose levels in people with diabetes. Unlike traditional finger prick self-monitoring of blood glucose (SMBG), CGM devices provide continuous and real-time glucose readings throughout the day and night.~CGM systems consist of a small sensor that is inserted under the skin to measure glucose levels in the interstitial fluid, a transmitter that sends the glucose data to a receiver or smartphone, which shows the glucose readings. The sensor measures glucose levels automatically at regular intervals, eliminating the need for frequent finger pricks.~CGM devices can track glucose trends, identify high or low glucose levels, and provide alerts for hypo- or hyperglycemia. This can help individuals make more informed decisions regarding their diabetes management, such as adjusting insulin doses, dietary choices, or physical activity levels.
Study: NCT05057221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uproleselan
Description: Uproleselan 20 mg/kg BID up to maximum dose of 2500 mg, infused IV over 20 minutes on days 1-7 or until hospital discharge. It should be administered intravenously (IV) into a peripheral line, a central catheter, or a peripherally inserted central line catheter (PICC). Infusion should take place at a steady rate over a period of 20 minutes ±2 minutes using a syringe pump or IV pump.
Study: NCT04893551

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tilvestamab
Description: Tilvestamab will be administered as IV infusion.
Study: NCT04852250

Intervention type: OTHER
Intervention: Virtual centralized multidisciplinary tumour board
Description: Evaluation of radiologic imaging and general condition by a multidisciplinary expert gremium to recommend either secondary intervention or resection of metastases or continuation of systemic treatment
Study: NCT05469529

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 5mcg dexmedetomidine to be given intrathecally along with 0.5% bupivacaine.
Study: NCT05535608

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SRW Cel System
Description: Dietary supplement